507 related articles for article (PubMed ID: 23451769)
1. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Frost C; Nepal S; Wang J; Schuster A; Byon W; Boyd RA; Yu Z; Shenker A; Barrett YC; Mosqueda-Garcia R; Lacreta F
Br J Clin Pharmacol; 2013 Nov; 76(5):776-86. PubMed ID: 23451769
[TBL] [Abstract][Full Text] [Related]
2. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
3. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Frost C; Garonzik S; Shenker A; Barrett YC; LaCreta F
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):974-984. PubMed ID: 34342172
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
Yamahira N; Frost C; Fukase H; Yu Z; Wang J; Pursley J; LaCreta F; Hiraoka M
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
[TBL] [Abstract][Full Text] [Related]
6. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
[TBL] [Abstract][Full Text] [Related]
7. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
[TBL] [Abstract][Full Text] [Related]
8. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
[TBL] [Abstract][Full Text] [Related]
9. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Upreti VV; Wang J; Barrett YC; Byon W; Boyd RA; Pursley J; LaCreta FP; Frost CE
Br J Clin Pharmacol; 2013 Dec; 76(6):908-16. PubMed ID: 23488672
[TBL] [Abstract][Full Text] [Related]
10. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
Wang X; Tirucherai G; Marbury TC; Wang J; Chang M; Zhang D; Song Y; Pursley J; Boyd RA; Frost C
J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
[TBL] [Abstract][Full Text] [Related]
13. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
Frost C; Shenker A; Gandhi MD; Pursley J; Barrett YC; Wang J; Zhang D; Byon W; Boyd RA; LaCreta F
Br J Clin Pharmacol; 2014 Oct; 78(4):877-85. PubMed ID: 24697979
[TBL] [Abstract][Full Text] [Related]
15. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
; Buller H; Deitchman D; Prins M; Segers A
J Thromb Haemost; 2008 Aug; 6(8):1313-8. PubMed ID: 18541000
[TBL] [Abstract][Full Text] [Related]
17. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
[TBL] [Abstract][Full Text] [Related]
18. Apixaban: a novel oral inhibitor of factor Xa.
Nutescu E
Am J Health Syst Pharm; 2012 Jul; 69(13):1113-26. PubMed ID: 22722590
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
Xuan D; McBride S; Wastall P; Porcari A; DiCarlo L; Boyd RA
Clin Pharmacol Drug Dev; 2016 Jan; 5(1):13-26. PubMed ID: 27119575
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
Zeitouni M; Giczewska A; Lopes RD; Wojdyla DM; Christersson C; Siegbahn A; De Caterina R; Steg PG; Granger CB; Wallentin L; Alexander JH;
J Am Coll Cardiol; 2020 Mar; 75(10):1145-1155. PubMed ID: 32164888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
